These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20578979)

  • 1. Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19.
    Kolukisaoglu Ü; Wendler C; Goerdes D; Diener A; Thurow K
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):876-86. PubMed ID: 20578979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interactions with piperazine-based 'party pill' drugs.
    Antia U; Tingle MD; Russell BR
    J Pharm Pharmacol; 2009 Jul; 61(7):877-82. PubMed ID: 19589229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of sesamin by cytochrome P450 in human liver microsomes.
    Yasuda K; Ikushiro S; Kamakura M; Ohta M; Sakaki T
    Drug Metab Dispos; 2010 Dec; 38(12):2117-23. PubMed ID: 20851877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY; Chen C; Yang Z; Rodrigues AD
    Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
    Desta Z; Soukhova NV; Flockhart DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of type II ligands in CYP2C9 and CYP3A4.
    Ahlström MM; Zamora I
    J Med Chem; 2008 Mar; 51(6):1755-63. PubMed ID: 18311908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
    Usmani KA; Karoly ED; Hodgson E; Rose RL
    Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR; Lasker JM; Johnson EF; Raucy JL
    Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
    Cai X; Wang RW; Edom RW; Evans DC; Shou M; Rodrigues AD; Liu W; Dean DC; Baillie TA
    Drug Metab Dispos; 2004 Jun; 32(6):584-6. PubMed ID: 15155548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.
    Marks BD; Smith RW; Braun HA; Goossens TA; Christenson M; Ozers MS; Lebakken CS; Trubetskoy OV
    Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):73-81. PubMed ID: 15090158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines.
    Yap CW; Chen YZ
    J Chem Inf Model; 2005; 45(4):982-92. PubMed ID: 16045292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes.
    Lewis DF; Lake BG; Ito Y; Dickins M
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):385-9. PubMed ID: 17059170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
    Yale SH; Glurich I
    J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.